EU Taxonomy Reporting for Pharma: Meeting Environmental Sustainability Disclosure Requirements

Environmental sustainability reporting has moved from a voluntary differentiator to a regulatory obligation for pharmaceutical companies operating in Europe. The EU Taxonomy Regulation, working in concert with the Corporate Sustainability Reporting Directive (CSRD), establishes a classification system that defines which economic activities qualify as environmentally sustainable and requires in-scope companies to disclose what proportion of their revenues, capital expenditures, and operating expenditures align with taxonomy criteria.

For pharmaceutical companies, this regulatory framework presents a distinctive set of challenges. The pharma industry does not fit neatly into the taxonomy’s activity classifications, which were initially designed around sectors with more direct environmental impacts such as energy, transportation, and construction. Yet the reporting obligations apply regardless of whether a company’s activities align with taxonomy-defined categories, and the disclosures themselves carry significant implications for investor relations, ESG ratings, access to sustainable finance, and stakeholder perception.

IT leaders, digital transformation teams, and quality operations executives within pharmaceutical organizations are increasingly finding that EU Taxonomy compliance demands the same caliber of data infrastructure, process rigor, and auditability that they apply to GxP-regulated systems. The reporting requirements cannot be met through manual data collection and spreadsheet-based analysis at the scale and reliability levels required. Building the digital foundations for taxonomy reporting is becoming a strategic priority alongside more traditional compliance investments.

Understanding the EU Taxonomy Regulation

The EU Taxonomy Regulation (Regulation 2020/852) entered into force in July 2020 and established a unified classification system for environmentally sustainable economic activities across the European Union. The regulation was designed to address a fundamental problem in sustainable finance: the absence of a common language and set of criteria for determining what qualifies as a green investment or sustainable business activity.

The taxonomy is built around a structured decision framework. For an economic activity to be classified as taxonomy-aligned (environmentally sustainable), it must satisfy four conditions simultaneously:

1. Substantial contribution: The activity must make a substantial contribution to at least one of the six environmental objectives defined in the regulation
2. Do no significant harm (DNSH): The activity must not significantly harm any of the other five environmental objectives
3. Minimum safeguards: The activity must comply with minimum social safeguards, including alignment with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights
4. Technical screening criteria: The activity must meet the specific technical screening criteria established in the delegated acts for the relevant environmental objective

The European Commission has adopted delegated acts that define technical screening criteria for activities contributing to climate change mitigation and climate change adaptation (the Climate Delegated Act) and for activities contributing to the remaining four environmental objectives (the Environmental Delegated Act). These criteria are detailed, quantitative where possible, and sector-specific.

The CSRD Connection and Reporting Obligations

The EU Taxonomy Regulation does not operate in isolation. Its reporting requirements are embedded within the broader framework of the Corporate Sustainability Reporting Directive, which substantially expands the scope and rigor of sustainability reporting for companies operating in the EU.

The CSRD replaced the earlier Non-Financial Reporting Directive (NFRD) and introduced several significant changes that affect pharmaceutical companies:

• Expanded scope: The CSRD applies to all large EU companies, all EU-listed companies (except listed micro-enterprises), and non-EU companies with significant EU operations meeting certain thresholds. This expanded scope captures many pharmaceutical companies that were not previously subject to mandatory sustainability reporting.
• European Sustainability Reporting Standards (ESRS): Companies reporting under the CSRD must follow the ESRS, which provide detailed disclosure requirements across environmental, social, and governance topics. The ESRS include specific cross-references to EU Taxonomy reporting, requiring companies to include taxonomy disclosures as part of their broader sustainability reporting.
• Mandatory assurance: CSRD reports, including taxonomy disclosures, must be subject to independent assurance. Initially, limited assurance is required, with a transition to reasonable assurance expected over time. This assurance requirement elevates the data quality and process control expectations for sustainability reporting to levels that pharmaceutical companies associate with financial reporting.
• Digital tagging: Sustainability reports must be prepared in a digital format that enables machine-readable access to the data. The European Single Electronic Format (ESEF) requires XBRL tagging of taxonomy disclosures, creating additional technical requirements for reporting systems.

The CSRD’s phased implementation timeline means that different companies become subject to reporting obligations at different times. Large public-interest entities with more than 500 employees were first to report (for fiscal year 2024). Other large companies follow for fiscal year 2025, and listed SMEs begin reporting for fiscal year 2026. Non-EU companies meeting the EU revenue threshold must report for fiscal year 2028.

How the EU Taxonomy Applies to Pharmaceutical Companies

The pharmaceutical industry’s relationship with the EU Taxonomy is complicated by the fact that drug manufacturing, research and development, and pharmaceutical distribution are not explicitly listed as taxonomy-eligible activities in the current delegated acts. This does not exempt pharmaceutical companies from taxonomy reporting; it means that their core business activities will generally show low taxonomy eligibility and alignment percentages.

However, pharmaceutical companies typically have several categories of activity that are taxonomy-eligible:

Building and Facility Operations

The acquisition, ownership, and renovation of buildings is a taxonomy-eligible activity under the climate change mitigation objective. Pharmaceutical companies with significant real estate portfolios, including manufacturing facilities, research laboratories, and office buildings, will find that their building-related capital and operating expenditures may qualify for taxonomy eligibility assessment. Buildings that meet specified energy performance standards can be taxonomy-aligned.

Energy Generation and Procurement

On-site renewable energy generation, energy efficiency improvements, and procurement of renewable electricity are taxonomy-eligible activities. Many pharmaceutical companies have invested in solar installations, cogeneration systems, and renewable energy procurement as part of their sustainability commitments. These investments can contribute to taxonomy-aligned CapEx and OpEx.

Transportation and Fleet

Vehicle fleet operations and logistics activities may be taxonomy-eligible under transportation categories. Companies transitioning to electric or low-emission vehicle fleets can capture these investments as taxonomy-aligned capital expenditures.

Water and Waste Management

Water treatment, waste management, and circular economy activities are covered by the environmental delegated act. Pharmaceutical manufacturing generates significant wastewater and waste streams, and investments in advanced treatment technologies or waste reduction programs may qualify for taxonomy alignment under the pollution prevention or circular economy objectives.

The Six Environmental Objectives and Pharma Relevance

The EU Taxonomy defines six environmental objectives, each with associated technical screening criteria for eligible activities. Understanding how each objective relates to pharmaceutical operations helps companies identify where their activities may qualify for taxonomy assessment.

Determining Taxonomy Alignment for Pharma Activities

The process of determining whether specific activities meet taxonomy alignment criteria is methodical but requires significant analytical effort. For each potentially eligible activity, companies must work through a multi-step assessment.

Step 1: Activity Identification and Classification

Map company activities to the taxonomy’s activity descriptions in the delegated acts. This requires detailed understanding of both the company’s operations and the taxonomy’s classification system. For pharmaceutical companies, the most relevant activity categories typically fall under construction and real estate, energy, transport, and water and waste management rather than under pharmaceutical manufacturing itself.

Step 2: Technical Screening Criteria Assessment

For each eligible activity, evaluate whether it meets the specific technical screening criteria for substantial contribution to the relevant environmental objective. These criteria are quantitative where possible. For example, building activities must meet specific energy performance thresholds expressed in terms of primary energy demand per square meter, and these thresholds vary by climate zone and building type.

Step 3: DNSH Assessment

Verify that the activity does not significantly harm any of the other five environmental objectives. The DNSH criteria for each activity are specified in the delegated acts and may include requirements such as compliance with specific environmental regulations, implementation of environmental management systems, or adherence to particular emission standards. This step often requires collecting environmental data that companies may not have systematically gathered before.

Step 4: Minimum Safeguards Verification

Confirm that the company meets minimum social safeguards across its operations, not just for the specific activity under assessment. This includes due diligence processes for human rights, anti-corruption, taxation, and fair competition aligned with international frameworks. Many pharmaceutical companies already have these frameworks in place through their existing compliance programs, but documentation may need to be formalized for taxonomy reporting purposes.

Key Performance Indicator Reporting Requirements

The EU Taxonomy requires companies to report three key performance indicators that quantify the proportion of their financial activity that is taxonomy-eligible and taxonomy-aligned. These KPIs form the core of taxonomy disclosure and are designed to give investors and other stakeholders a standardized view of a company’s environmental sustainability profile.

Turnover KPI

The turnover KPI measures the proportion of net revenue derived from products or services associated with taxonomy-aligned activities. For most pharmaceutical companies, this KPI will be near zero because pharmaceutical product sales are not a taxonomy-eligible activity under the current delegated acts. While this may seem like an unfavorable disclosure, it is consistent across the pharmaceutical sector and investors with sector expertise understand this structural characteristic.

Capital Expenditure (CapEx) KPI

The CapEx KPI measures the proportion of capital expenditure associated with taxonomy-aligned activities or with CapEx plans to expand or achieve taxonomy-aligned activities. This is typically the most meaningful KPI for pharmaceutical companies, as investments in energy-efficient buildings, renewable energy installations, and fleet electrification can contribute to taxonomy-aligned capital expenditure. Companies with active capital investment programs in sustainability-related areas may show meaningful CapEx alignment percentages even when turnover alignment is minimal.

Operating Expenditure (OpEx) KPI

The OpEx KPI measures the proportion of direct non-capitalized costs related to taxonomy-aligned activities. Eligible operating expenditure categories include research and development, building renovation measures, short-term leases, maintenance and repair, and other direct expenditures relating to the day-to-day servicing of assets that are taxonomy-aligned. The OpEx KPI has a narrower scope than many companies initially expect, and careful application of the definition is needed to avoid overstating eligible expenditure.

Data Collection and Management Challenges

EU Taxonomy reporting demands data that most pharmaceutical companies have not historically collected in a systematic, auditable manner. The data challenges fall into several categories that require coordinated attention from finance, sustainability, operations, and IT functions.

Financial Data Granularity

Taxonomy KPI calculation requires mapping financial data to specific economic activities at a level of granularity that standard financial reporting systems often do not provide. A capital expenditure line item for building renovation, for example, must be disaggregated to identify which portions relate to energy efficiency improvements that might meet taxonomy criteria versus general maintenance that would not. This level of activity-level financial data frequently requires supplementary data collection processes or enhancements to existing financial coding structures.

Environmental Performance Data

The technical screening criteria and DNSH assessments require environmental performance data such as energy consumption per square meter, greenhouse gas emissions by scope and source, water consumption and discharge quality, waste generation and recovery rates, and compliance with specific environmental regulations. Collecting this data at the individual activity level rather than at the facility or corporate level is a significant step up in measurement granularity for many organizations.

Supply Chain and Value Chain Data

Some DNSH assessments and minimum safeguards evaluations require information about supply chain and value chain practices. For pharmaceutical companies with complex global supply chains, gathering reliable data on supplier environmental and social practices adds another layer of data collection complexity.

Cross-Functional Data Integration

No single function within a pharmaceutical company owns all the data needed for taxonomy reporting. Finance owns the financial data, facilities management owns building energy data, procurement owns supply chain data, EHS (environment, health, and safety) owns environmental performance data, and legal or compliance owns minimum safeguards documentation. Integrating data from these disparate sources into a coherent taxonomy disclosure requires cross-functional coordination and, ideally, integrated data management infrastructure.

Digital Infrastructure for Taxonomy Compliance

Given the data intensity, cross-functional complexity, and assurance requirements of EU Taxonomy reporting, building appropriate digital infrastructure is not optional. Organizations relying on manual processes and spreadsheets will find that the volume, complexity, and auditability requirements exceed what these tools can reliably deliver.

ESG Data Management Platforms

Purpose-built ESG data management platforms provide structured frameworks for collecting, validating, and reporting sustainability data including taxonomy disclosures. These platforms typically offer pre-built taxonomy assessment workflows, automated data validation rules, audit trail capabilities, and reporting templates that align with ESRS disclosure requirements. For pharmaceutical companies newly subject to CSRD reporting, these platforms can significantly accelerate implementation compared to building custom solutions.

ERP and Financial System Integration

Taxonomy KPI calculation requires tight integration with enterprise resource planning (ERP) and financial reporting systems. The CapEx and OpEx denominators must be derived from the same financial data used for annual financial statements, and the numerators require activity-level financial classification that ideally originates from the financial system rather than being layered on externally. Major ERP vendors have introduced or are developing taxonomy reporting modules, but implementation requires careful configuration to match each company’s chart of accounts and activity classification structure.

Environmental Data Systems

Energy management systems, environmental monitoring platforms, and building management systems provide the environmental performance data needed for technical screening criteria assessment. Integrating these systems with the taxonomy reporting platform reduces manual data handling and improves data reliability. For pharmaceutical companies with existing environmental management systems for GxP or regulatory compliance, extending these systems to support taxonomy reporting leverages existing infrastructure investments.

Assurance and Audit Readiness

The CSRD’s mandatory assurance requirement for sustainability reporting, including taxonomy disclosures, introduces a level of external scrutiny that many organizations have not previously applied to environmental data. Preparing for this assurance is a critical implementation workstream that should begin well before the first reporting period.

Limited vs. Reasonable Assurance

The CSRD initially requires limited assurance, which provides a moderate level of confidence that the reported information is free from material misstatement. The European Commission has indicated an intention to transition to reasonable assurance, which provides a higher level of confidence comparable to financial statement audits, once standards and capabilities have matured. Organizations should plan for reasonable assurance from the outset, as retrofitting processes and controls to meet the higher standard is more disruptive than building them correctly initially.

Internal Controls Framework

Effective assurance readiness requires establishing internal controls over sustainability reporting that parallel the controls applied to financial reporting. This includes controls over data collection completeness, accuracy of calculation methodologies, appropriateness of activity classification decisions, and reliability of environmental performance measurements. Organizations with established internal control frameworks for financial reporting (SOX compliance, for example) can extend these frameworks to cover taxonomy reporting, but the extension requires careful design because the data types and sources are fundamentally different.

Documentation and Methodology Standards

Assurance providers will expect documented methodologies for every significant judgment and calculation involved in taxonomy reporting. This includes the basis for determining which activities are taxonomy-eligible, the approach to allocating financial data across activities, the methods used to measure environmental performance against technical screening criteria, and the evidence supporting DNSH and minimum safeguards compliance. Maintaining this documentation in an accessible, version-controlled format is essential.

Global Implications Beyond the EU

While the EU Taxonomy and CSRD are European regulations, their implications extend to pharmaceutical companies headquartered outside the EU, including U.S.-based firms with significant European operations or investors.

Extraterritorial Scope of CSRD

Non-EU companies with net turnover exceeding EUR 150 million in the EU and at least one subsidiary or branch in the EU exceeding certain thresholds are subject to CSRD reporting requirements, including taxonomy disclosures. This captures many global pharmaceutical companies with substantial European revenue. The reporting requirements for non-EU companies will apply beginning with fiscal year 2028, providing a runway for preparation but also a firm deadline that organizations should be planning toward now.

Influence on Global Standards

The EU Taxonomy has influenced the development of taxonomy frameworks in other jurisdictions, including the UK, Singapore, South Africa, and several other countries. While these taxonomies are not identical to the EU version, the conceptual framework of defining environmentally sustainable activities through technical screening criteria is spreading globally. Companies that build robust taxonomy reporting capabilities for EU compliance will find these capabilities transferable to emerging requirements in other markets.

Investor and Financial Market Expectations

Even for pharmaceutical companies not directly subject to EU Taxonomy reporting obligations, investor expectations for sustainability disclosure are increasingly shaped by the taxonomy’s framework. ESG-focused investors use taxonomy alignment data as an input to investment decisions, and sustainable finance regulations such as the Sustainable Finance Disclosure Regulation (SFDR) require financial market participants to report on the taxonomy alignment of their investment portfolios. This creates demand-side pressure for taxonomy disclosure that extends beyond the regulation’s direct scope.

Competitive and Reputational Considerations

Pharmaceutical companies that can demonstrate meaningful taxonomy-aligned investments, even if the overall percentages are modest relative to other sectors, signal commitment to environmental sustainability in a way that is increasingly valued by customers, employees, and regulators. Conversely, companies that produce incomplete or unreliable taxonomy disclosures risk reputational damage in an environment where greenwashing scrutiny is intensifying.

Building Your Implementation Roadmap

Implementing EU Taxonomy reporting capability is a multi-workstream effort that typically spans twelve to eighteen months from project initiation to first disclosure-ready reporting. The following roadmap outlines the key phases and activities that pharmaceutical companies should plan for.

Phase 1: Scoping and Gap Assessment (Months 1-3)

Begin with a comprehensive assessment of the organization’s current sustainability reporting capabilities, data availability, and system infrastructure relative to taxonomy requirements. This phase should produce a clear picture of which activities are potentially taxonomy-eligible, what data is currently available versus what needs to be collected, which systems need to be enhanced or connected, and what the organization’s likely taxonomy KPI profile will look like. The output of this phase is an implementation plan with resource estimates, timeline, and budget.

Phase 2: Methodology and Process Design (Months 3-6)

Develop the detailed methodologies for activity classification, financial data allocation, technical screening criteria assessment, DNSH evaluation, and minimum safeguards verification. Design the data collection processes and workflows that will produce the information needed for each methodology. Establish data quality standards and validation rules. Document all methodological decisions and the rationale supporting them.

Phase 3: System Implementation and Integration (Months 4-9)

Implement the technology infrastructure to support taxonomy reporting. This may include deploying an ESG data management platform, configuring ERP system enhancements for activity-level cost coding, establishing data feeds from environmental monitoring systems, and building reporting and analytics capabilities. System implementation should be prioritized based on the data gaps identified in Phase 1, focusing first on the most critical data sources for the organization’s specific taxonomy KPI profile.

Phase 4: Pilot Reporting and Validation (Months 8-12)

Conduct a pilot reporting cycle using the implemented processes and systems to produce draft taxonomy disclosures. This pilot serves multiple purposes: validating that the data collection processes produce reliable outputs, testing the calculation methodologies against real data, identifying remaining data gaps or quality issues, and producing example disclosures that can be reviewed by internal stakeholders and, ideally, by the intended assurance provider. Findings from the pilot should drive iterative improvements to processes and systems before the first mandatory reporting period.

Phase 5: Assurance Preparation and Go-Live (Months 10-18)

Formalize the internal controls framework for taxonomy reporting, complete documentation of all methodologies and processes, engage with the assurance provider to confirm readiness, and produce the first reporting-period taxonomy disclosures. Establish an ongoing governance structure for taxonomy reporting that includes clear ownership, periodic review of methodology appropriateness, and a process for incorporating regulatory updates as the taxonomy framework evolves.

EU Taxonomy reporting is becoming an inescapable element of corporate accountability for pharmaceutical companies with European operations or investors. While the current taxonomy structure may not fully capture the environmental impacts and sustainability initiatives most relevant to the pharmaceutical industry, the reporting obligation provides both a compliance imperative and an opportunity to strengthen the organization’s environmental data infrastructure. Companies that approach taxonomy reporting as a strategic investment in data capability and stakeholder transparency, rather than merely a compliance exercise, will extract lasting value from the effort.

At Sakara Digital, we help pharmaceutical and life sciences organizations design and implement the digital infrastructure needed for EU Taxonomy and CSRD compliance, from ESG data platforms and ERP integrations to internal controls frameworks and assurance readiness programs. If your organization is preparing for taxonomy reporting, contact our team to discuss how we can accelerate your implementation and ensure audit-ready reporting from day one.